ZMB Member Ken Herrmann
ZMB Member
Ken Herrmann
Next ZMB-Member
Prof. Dr. Ken Herrmann
University Hospital Essen
Hufelandstr. 55
45122 Essen
- +49 201 723 2073
- Website
- Press Releases
- Selected Publications
- Publication Metrics
-

- ZMB Research Program
Oncology
Research Overview
- Development, application of new radiopharmaceuticals
- Diagnosis and therapy of thyroid carcinoma
- Diagnostics and therapy of endocrine tumors
- Diagnostics and therapy of prostate cancer
- Clinical use, optimization of PET, PET / CT
Selected Publications
-
Advances and challenges in precision imagingIn: The Lancet Oncology, Vol. 26, 2025, Nr. 1, pp. e34 – e45
-
The molecular blueprint of targeted radionuclide therapyIn: Nature Reviews Clinical Oncology, Vol. 22, 2025, Nr. 11, pp. 869 – 894
-
[⁶⁸Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation : A single-centre, single-arm, interventional, phase 2 trialIn: The Lancet Oncology, Vol. 26, 2025, Nr. 9, pp. 1204 – 1214DOI (Open Access)
-
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer : A multicentre retrospective studyIn: The Lancet Oncology, Vol. 25, 2024, Nr. 9, pp. 1188 – 1201DOI (Open Access)
-
Radiotherapy and theranostics : a Lancet Oncology CommissionIn: The Lancet Oncology, Vol. 25, 2024, Nr. 11, pp. e545 – e580
-
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer : a consensus recommendation from the EORTC Imaging and Breast Cancer GroupsIn: The Lancet Oncology, Vol. 24, 2023, Nr. 8, pp. e331 – e343DOI, Online Full Text (Open Access)
-
Health-related quality of life and pain outcomes with [¹⁷⁷Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION) : a multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology, Vol. 24, 2023, Nr. 6, pp. 597 – 610
-
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI) : A Single-Center Prospective Two-Arm StudyIn: Clinical Cancer Research, Vol. 28, 2022, Nr. 19, pp. 4194 – 4202DOI (Open Access)
-
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification : A post-hoc analysis of the PETAL trialIn: Leukemia, Vol. 36, 2022, Nr. 12, pp. 2845 – 2852DOI (Open Access)
-
Radiotheranostics in oncology : current challenges and emerging opportunitiesIn: Nature Reviews Clinical Oncology, Vol. 19, 2022, Nr. 8, pp. 534 – 550DOI, Online Full Text (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research, Vol. 28, 2022, Nr. 19, pp. 4346 – 4353DOI (Open Access)
-
Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection : A Multicenter Prospective Phase 3 Imaging TrialIn: JAMA Oncology, Vol. 7, 2021, Nr. 11, pp. 1635 – 1642
-
Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer : An international, multicentre, retrospective studyIn: The Lancet Oncology, Vol. 22, 2021, Nr. 8, pp. 1115 – 1125DOI (Open Access)
-
Nuclear medicine theranostics comes of ageIn: The Lancet Oncology, Vol. 22, 2021, Nr. 11, pp. 1497 – 1498
-
In vivo biodistribution of calcium phosphate nanoparticles after intravascular, intramuscular, intratumoral, and soft tissue administration in mice investigated by small animal PET/CTIn: Acta Biomaterialia, Vol. 109, 2020, pp. 244 – 253
-
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapyIn: The Lancet Oncology, Vol. 21, 2020, Nr. 9, pp. e431 – e443DOI, Online Full Text (Open Access)
-
Radiotheranostics : A roadmap for future developmentIn: The Lancet Oncology, Vol. 21, 2020, Nr. 3, pp. e146 – e156DOI, Online Full Text (Open Access)
-
Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer : A Prospective Single-Arm Clinical TrialIn: JAMA Oncology, Vol. 5, 2019, Nr. 6, pp. 856 – 863DOI (Open Access)
-
NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 RadioembolizationIn: Liver Cancer, Vol. 8, 2019, Nr. 6, pp. 491 – 504DOI, Online Full Text (Open Access)
-
Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancerIn: Clinical Cancer Research, Vol. 25, 2019, Nr. 24, pp. 7448 – 7454DOI (Open Access)
-
The beginning of the end for conventional RECIST — novel therapies require novel imaging approachesIn: Nature Reviews Clinical Oncology, Vol. 16, 2019, Nr. 7, pp. 442 – 458
-
Consensus on molecular imaging and theranostics in prostate cancerIn: The Lancet Oncology, Vol. 19, 2018, Nr. 12, pp. e696 – e708
-
Extrahepatic Comorbidities Do Not Alter the Safety and Efficacy of Radioembolization of NAFLD-Associated HCCIn: Hepatology, Vol. 68, 2018, Nr. Suppl. 1, pp. 852A – 853A
-
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer : a consensus recommendation from the EORTC Imaging GroupIn: The Lancet Oncology, Vol. 19, 2018, Nr. 10, pp. e534 – e545DOI, Online Full Text (Open Access)
-
A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signalingIn: Leukemia, Vol. 27, 2013, Nr. 12, pp. 2301 – 2310
